Unlock instant, AI-driven research and patent intelligence for your innovation.

Finafloxacin suspension compositions

a technology of finafloxacin and composition, which is applied in the direction of drug composition, antibacterial agent, inorganic non-active ingredients, etc., can solve the problems of low solubility and stability of finafloxacin solution composition, undesired precipitates, etc., and achieve the effect of increasing the soluble fraction of finafloxacin

Inactive Publication Date: 2016-09-29
MERLION PHARMA PTE LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is a method for treating infected tissue using a topical suspension composition containing finafloxacin. This treatment involves applying the suspension once a day to the affected area for an extended period of time. The suspension formulation provides immediate antimicrobial activity and is effective in low-frequency dosing regimes. This method can help to improve the effectiveness and duration of treatment for infected tissue.

Problems solved by technology

However, solution compositions of finafloxacin suffered from low solubility and stability at the optimum pH, often producing undesired precipitates.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Finafloxacin suspension compositions
  • Finafloxacin suspension compositions
  • Finafloxacin suspension compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0050]

Ingredient% w / vFinafloxacin0.1 to 1.0Tyloxapol0.01Hydroxyethylcellulose0.2Sodium chloride0.86Magnesium chloride0.06Benzalkonium chloride0.005Sodium hydroxideAdjust pH to 6Purified Waterq.s. 100%

example 2

[0051]

Ingredient% w / vFinafloxacin0.1 to 1.0Lactic Acid0.18Glycerin2.4Boric Acid0.3TromethamineAdjust pH to 6Purified Waterq.s. 100%

example 3

[0052]

Ingredient% w / vFinafloxacin Free Base0.3Tyloxapol0.01Hydroxyethylcellulose0.2Sodium chloride0.86Magnesium chloride0.12Benzalkonium chloride0.005Sodium hydroxideAdjust pH to 5.8Purified Waterq.s. 100%

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a suspension composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin free base or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.

Description

TECHNICAL FIELD OF THE INVENTION[0001]The present invention generally relates to suspension compositions comprising a fluoroquinolone. The present invention specifically relates to suspension compositions comprising finafloxacin or a finafloxacin derivative.BACKGROUND OF THE INVENTION[0002]Quinolone antibiotics are known to have desirable broad-spectrum antimicrobial properties. For example, quinolone compounds for use in the treatment of ophthalmic, otic, and nasal conditions are disclosed in U.S. Pat. No. 6,716,830, the entire contents of which are incorporated by reference herein.[0003]For use in pharmaceutical therapeutics, quinolone antibiotics must be formulated as stable, efficacious compositions. Unstable compositions can precipitate particulate matter when stored for a period of time, or can experience degradation of the active pharmaceutical ingredient or an excipient. Such compositions are unlikely to be approved by regulatory agencies due to safety concerns and other con...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5383A61K9/10A61K47/38A61K31/573A61K9/00A61K47/02
CPCA61K31/5383A61K9/0048A61K47/02A61K9/0043A61K31/573A61K9/10A61K9/0046A61K47/38A61P11/02A61P27/02A61P27/16A61P29/00A61P31/00A61P31/04A61P9/00
Inventor BOUDREAUX, BRENT G.BRIDLE, MARK J.HUYNH, BRYAN H.GHOSH, MALAYCHOWHAN, MASOOD A.ALANI, LAMANKABRA, BHAGWATI P.
Owner MERLION PHARMA PTE LTD